These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 12569483)

  • 21. In silico and in vitro elucidation of BH3 binding specificity toward Bcl-2.
    London N; Gullá S; Keating AE; Schueler-Furman O
    Biochemistry; 2012 Jul; 51(29):5841-50. PubMed ID: 22702834
    [TBL] [Abstract][Full Text] [Related]  

  • 22. (alpha/beta+alpha)-peptide antagonists of BH3 domain/Bcl-x(L) recognition: toward general strategies for foldamer-based inhibition of protein-protein interactions.
    Sadowsky JD; Fairlie WD; Hadley EB; Lee HS; Umezawa N; Nikolovska-Coleska Z; Wang S; Huang DC; Tomita Y; Gellman SH
    J Am Chem Soc; 2007 Jan; 129(1):139-54. PubMed ID: 17199293
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and helical structure of lactam bridged BH3 peptides derived from pro-apoptotic Bcl-2 family proteins.
    Yang B; Liu D; Huang Z
    Bioorg Med Chem Lett; 2004 Mar; 14(6):1403-6. PubMed ID: 15006371
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structural basis of Bcl-xL recognition by a BH3-mimetic α/β-peptide generated by sequence-based design.
    Lee EF; Smith BJ; Horne WS; Mayer KN; Evangelista M; Colman PM; Gellman SH; Fairlie WD
    Chembiochem; 2011 Sep; 12(13):2025-32. PubMed ID: 21744457
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak.
    Willis SN; Fletcher JI; Kaufmann T; van Delft MF; Chen L; Czabotar PE; Ierino H; Lee EF; Fairlie WD; Bouillet P; Strasser A; Kluck RM; Adams JM; Huang DC
    Science; 2007 Feb; 315(5813):856-9. PubMed ID: 17289999
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro effects of the BH3 mimetic, (-)-gossypol, on head and neck squamous cell carcinoma cells.
    Oliver CL; Bauer JA; Wolter KG; Ubell ML; Narayan A; O'Connell KM; Fisher SG; Wang S; Wu X; Ji M; Carey TE; Bradford CR
    Clin Cancer Res; 2004 Nov; 10(22):7757-63. PubMed ID: 15570010
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rationale for Bcl-xL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies.
    Petros AM; Nettesheim DG; Wang Y; Olejniczak ET; Meadows RP; Mack J; Swift K; Matayoshi ED; Zhang H; Thompson CB; Fesik SW
    Protein Sci; 2000 Dec; 9(12):2528-34. PubMed ID: 11206074
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structure-activity relationships of Bak derived peptides: affinity and specificity modulations by amino acid replacement.
    Frey V; Viaud J; Subra G; Cauquil N; Guichou JF; Casara P; Grassy G; Chavanieu A
    Eur J Med Chem; 2008 May; 43(5):966-72. PubMed ID: 17692431
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Designed BH3 peptides with high affinity and specificity for targeting Mcl-1 in cells.
    Foight GW; Ryan JA; Gullá SV; Letai A; Keating AE
    ACS Chem Biol; 2014 Sep; 9(9):1962-8. PubMed ID: 25052212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of dimerization of Bcl-2 family proteins by surface plasmon resonance.
    Xie Z; Reed JC
    Methods Enzymol; 2000; 322():266-74. PubMed ID: 10914024
    [No Abstract]   [Full Text] [Related]  

  • 31. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins.
    Willis SN; Chen L; Dewson G; Wei A; Naik E; Fletcher JI; Adams JM; Huang DC
    Genes Dev; 2005 Jun; 19(11):1294-305. PubMed ID: 15901672
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The structure of the C-terminal domain of the pro-apoptotic protein Bak and its interaction with model membranes.
    Martínez-Senac Mdel M; Corbalán-García S; Gómez-Fernández JC
    Biophys J; 2002 Jan; 82(1 Pt 1):233-43. PubMed ID: 11751312
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Locating Herpesvirus Bcl-2 Homologs in the Specificity Landscape of Anti-Apoptotic Bcl-2 Proteins.
    Foight GW; Keating AE
    J Mol Biol; 2015 Jul; 427(15):2468-2490. PubMed ID: 26009469
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting anti-apoptotic Bcl2 proteins with scyllatoxin-based BH3 domain mimetics.
    Harris MM; Coon Z; Alqaeisoom N; Swords B; Holub JM
    Org Biomol Chem; 2016 Jan; 14(2):440-446. PubMed ID: 26563651
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel BH3 mimetic S1 potently induces Bax/Bak-dependent apoptosis by targeting both Bcl-2 and Mcl-1.
    Zhang Z; Song T; Zhang T; Gao J; Wu G; An L; Du G
    Int J Cancer; 2011 Apr; 128(7):1724-35. PubMed ID: 20503275
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Erythrocyte survival is promoted by plasma and suppressed by a Bak-derived BH3 peptide that interacts with membrane-associated Bcl-X(L).
    Walsh M; Lutz RJ; Cotter TG; O'Connor R
    Blood; 2002 May; 99(9):3439-48. PubMed ID: 11964315
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro selection and characterization of Bcl-X(L)-binding proteins from a mix of tissue-specific mRNA display libraries.
    Hammond PW; Alpin J; Rise CE; Wright M; Kreider BL
    J Biol Chem; 2001 Jun; 276(24):20898-906. PubMed ID: 11283018
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Binding modes of Bcl-2 homology 3 (BH3) peptides with anti-apoptotic protein A1 and redesign of peptide inhibitors: a computational study.
    Chen Y; Wang J; Zhang J; Wang W
    J Biomol Struct Dyn; 2018 Nov; 36(15):3967-3977. PubMed ID: 29137527
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peptide screening to knockdown Bcl-2's anti-apoptotic activity: implications in cancer treatment.
    Raghav PK; Verma YK; Gangenahalli GU
    Int J Biol Macromol; 2012 Apr; 50(3):796-814. PubMed ID: 22155216
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Apoptosis: Bax to Bak.
    Mitchell A
    Nat Rev Mol Cell Biol; 2001 Jan; 2(1):6. PubMed ID: 11413453
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.